S
LXEO icon

SignatureFD’s Lexeo Therapeutics LXEO Stock Holding History

SignatureFD’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$740 Sell
159
-41
-21% -$222 ﹤0.01% 3305
2026
Q1 		$1.15K Sell
200
-90
-31% -$638 ﹤0.01% 3179
2025
Q4 		$2.88K Buy
290
+112
+63% +$1.02K ﹤0.01% 2873
2025
Q3 		$1.18K Buy
+178
New +$861 ﹤0.01% 3053

Other funds holding LXEO

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SignatureFD's LXEO Position: Q2 2026 in Review

SignatureFD reduced its Lexeo Therapeutics (LXEO) stake by 21% in Q2 2026, selling an estimated $222 and leaving 159 shares worth $740. The position accounts for ﹤0.01% of the portfolio, ranked #3305.

SignatureFD first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.88K in Q4 2025. 19 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • SignatureFD held 159 shares of Lexeo Therapeutics worth $740 as of Q2 2026.
  • SignatureFD sold 41 Lexeo Therapeutics shares in Q2 2026, an estimated $222.
  • Lexeo Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3305 holding.
  • SignatureFD first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • SignatureFD's Lexeo Therapeutics position peaked at $2.88K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.